TrialSignal
Clinical trial intelligence report
Protective Gr1low Monocytes and Macrophages in Compensated Cardiac Hypertrophy to Limit Decompensation and Heart Damaging
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT04022330-Jul 28, 2026
NCT ID
NCT04022330
Status
UNKNOWN
Phase
Not Yet Recruiting
Sponsor
Assistance Publique - Hôpitaux de Paris
Executive brief
Investment-Ready Snapshot
The PROMOMA trial, sponsored by Assistance Publique
Hôpitaux de Paris, aims to elucidate the protective role of Gr1low monocytes and macrophages in patients with compensated cardiac hypertrophy. Given the increasing prevalence of heart failure and its associated healthcare costs, successful outcomes could lead to novel therapeutic strategies that may significantly impact the heart failure market. The trial's focus on identifying specific biomarkers for compensated cardiac hypertrophy may position the sponsor favorably in the competitive landscape, particularly if these biomarkers can be translated into diagnostic or therapeutic products. The anticipated completion date in April 2024 suggests a timeline for potential data readouts that could inform future development pathways and partnerships.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04022330
Indication
Left Ventricular Hypertrophy
Modality
RNA therapy
Target
Cardiac macrophages and their role in the transition from compensated cardiac hypertrophy to heart failure.
Intervention
Blood sampling
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.